Previous 10 | Next 10 |
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 fin...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Instil Bio Inc. (TIL) is expected to report $-0.14 for Q3 2023
2023-08-14 09:53:11 ET Instil Bio press release ( NASDAQ: TIL ): Q2 GAAP EPS of -$0.14. As of June 30, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $202.9 million, which consists of $21.8 million in cash and cash equi...
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements ...
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITI...
2023-05-11 09:51:16 ET Instil Bio press release ( NASDAQ: TIL ): Q1 GAAP EPS of -$0.44. As of March 31, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $223.9 million, which consists of $27.4 million in cash and cash e...
ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H ’ 2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”...
2023-03-31 09:19:44 ET Instil Bio press release ( NASDAQ: TIL ): Q4 GAAP EPS of -$0.41 in-line. As of December 31, 2022, Instil had $260.9 million in total cash and cash equivalents and marketable securities, comprised of $43.7 million in cash and cash equiv...
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil...
News, Short Squeeze, Breakout and More Instantly...
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent...
2024-04-16 19:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...